We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Warns Wockhardt Over Violations at Illinois Plant

FDA Warns Wockhardt Over Violations at Illinois Plant

June 6, 2014

Inspections at beleaguered Indian generics firm Wockhardt’s Illinois plant have turned up quality control issues ranging from poor cleanliness to shoddy product testing and incomplete record-keeping, the FDA said.

In a 483 inspection report to Wockhardt dated March 26 and released May 30, the FDA investigator identified multiple violations during a series of inspections from January to March at the firm’s Morton Grove Pharmaceuticals facility.

Among them, the plant’s quality-control unit did not fully monitor systems designed to assure the safety and quality of drug products, the investigator wrote. The facility also failed to keep complete records, he said. The records that are kept, however, are easy to delete. A general login on one computer “allows data stored on the hard drives of these instruments to be changed or deleted by any user,” the inspector noted.

Other violations included:

  • Wockhardt doesn’t thoroughly review batch failures and unexplained discrepancies. It fails to document out-of-specification investigations, doesn’t differentiate between different kinds of investigations and doesn’t properly catalogue its findings.
  • The quality control unit itself lacks the necessary authority to review records and track data.
  • Not all workers receive the necessary current good manufacturing practice (GMP) training.
  • Sanitary conditions are not adequately maintained. At least one worker was seen moving through the gowning area and into the drug manufacturing area without scrubbing up first. The catch basin of a hand dryer isn’t sufficiently clean and allows water to pool instead of fully draining.  

This is not the first time Wockhardt has had GMP violations, a problem that has hit other Indian drug firms as well. Wockhardt’s recent troubles include bans on five of its products in the U.S. and recalls of 16 more in the UK.

Wockhardt did not return a request for comment by press time.

Prevent FDA warnings. Better prepare for your next FDA inspection by purchasing Inspection Preparation Training for Drugmakers.

Pharmaceuticals Inspections and Audits

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared

  • FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing